US FDA Bans More Products from Ranbaxy
January 24, 2014 2:17 PM EST
The U.S. Food and Drug Administration said on Thursday it has banned more products from drugmaker Ranbaxy Laboratories (RANB.NS) from entering the United States due to manufacturing violations.
A Ranbaxy office building in Mohali
The FDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa, India "to prevent substandard quality products from reaching U.S. consumers."
The move follows an FDA inspection of the facility which identified significant violations of good manufacturing practices.
Staff at the Toansa facility were found to have retested raw materials and other ingredients after the items failed analytical testing "in order to produce acceptable findings," and did not report or investigate the failures, the FDA said.
The ban is the latest in a series of measures taken by the FDA to keep substandard products made by Ranbaxy out of the U.S. market. The FDA previously banned products from the company's facilities in Paonta Sahib, Dewas and Mohali as part of a consent decree designed to ensure compliance with good manufacturing practices.
The FDA's latest move means Ranbaxy's products are all but entirely banned from the United States.
Most Popular Slideshows
Join the Conversation
- Chilling: New ISIS Video Addresses Australia; Aussie Teen Delivers Message
- The Pirate Bay Blockade: Cost Of Blocking Websites Like TPB Is Ridiculously High
- Xiaomi Mi4 And MiPad Prices Likely Slashed, Thanks To Rivals Oppo, OnePlus And Meizu
- Virginia Woman Who Posted Naked Image Of Ex-BF’s New Partner 1st Person Charged Under Revenge Porn Law
- No Mercy: ISIS, Father Stones to Death Daughter for Alleged Adultery
- Meizu MX4 Pro To Arrive In November In Black And White Colours, Features Higher Than QHD Display, Exynos 5430 SoC And 3 GB RAM
- iOS 8 Jailbreak Release Date is Doomed as Team Evad3rs Opts Out, Pangu Hits Snag – Report